June 3, 2022
Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity
Phase 1 Study results for PSB205, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, provides proof-of-concept and early clinical validation of the MabPair platform